OncoDaily’s Post

RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer🩺 New data from the Phase 3 MARIPOSA study, presented at IASLC 2024, shows that RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) significantly improves long-term survival compared to osimertinib in EGFR-mutant advanced lung cancer. Johnson & Johnson Joshua Bauml Shirish Gadgeel For more details, visit https://lnkd.in/eYJwsVU3 #lcsm #LungCancer #OncoDaily #Oncology #Cancer #Health #Medicine

Great list to check how we are doing in regard to cancer prevention and a healthy lifestyle in general. #cancer #prevention #healthpromotion

#IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with #EndometrialCancer. This is the key finding from the Phase 1/2 ENDOLUNG clinical trial published in the prestigious scientific journal "BMC Cancer": https://lnkd.in/dAiiaiM3 The trial benefited from the contribution of global key opinion leaders from 9 hospitals in Spain and France, including the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Gustave Roussy in Paris, Hospital Clínico Universitario de Valencia in Valencia, Centre Léon Bérard in Lyon, Hospital Universitario Virgen del Rocío in Seville, Institut Paoli-Calmettes in Marseille and the Catalan Institute of Oncology in Badalona, l'Hospitalet and Girona. #GynCancer #oncology #cancer #innovation

This is the updated #Algorithm for #BladderCancer. Nivo/Gem/Cis was not approved at the time of this discussion w/ Karine Tawagi and Siamak Daneshmand but has been incorporated in this is mage below. #gusm #MedEd #OncEd Cancer Network #Oncology #Cancer #TreatmentAlgorithm #EvPembro #Cystectomy #Sacituzumab #Erdafitinib #BCGShortage

We are trying to help our next generation to have the chance to understand cancer better and give better treatment to cancer patients. Prof. Ghassan Abou-Alfa joins OncoDaily as we continue the Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer 🎗️ Follow the link below: https://lnkd.in/dNgP7N6U #Cancer #CancerResearch #ColorectalCancer #GlobalCancerMovement #CancerTreatment #CancerPatient #Medicine #Health #Oncology #OncoDaily

💊 Cambridge research has led to a life-saving cancer drug. In 1999, Professor Sir Stephen (Steve) Jackson set up a team of scientists that created olaparib, a new class of cancer drug, which has now been used to treat over 140,000 patients globally and changed the outlook for people with breast, ovarian, prostate and pancreatic cancers. Find out how we're #ChangingTheStoryOfCancer 👉 https://lnkd.in/exCesBsY #CambridgeUniversity #UniversityOfCambridge #Cambridge #Cancer #CancerDiagnosis

European Cancer Organisation - The PRAISE-U Consortium meeting in Porto The European Cancer Organisation recently hosted the PRAISE-U Consortium meeting in Porto, Portugal, marking a significant moment in the project's development. One year into the initiative, partners presented their progress on pilot sites across Europe. PRAISE-U is an EU co-funded project aimed at enhancing prostate cancer screening through a risk-based approach. https://lnkd.in/ecwa9BaX #OncoDaily #Oncology #Cancer #Health #Medicine #ProstateCancer #CancerScreening

🔬 Advances in Immunotherapy for Head and Neck Cancer from ESMO 2024 Dr Willem Lybaert (University Hospital Antwerp) presents the JADE trial, investigating dostarlimab after chemoradiotherapy (CRT) in patients with PD-L1-positive LA-HNSCC. This phase III study, recruiting patients in 21 countries including Belgium, aims to improve the event-free survival in this setting. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #HeadandNeckCancer #Oncology #Immunotherapy #CancerResearch

Live NOW: Colorectal Cancer Worldwide: WHO Perspective. Join Andre Ilbawi at the Global Cancer Movement: Challenging the Status Quo Conference, as he discusses the critical importance of screening. To learn more and register the link below:  https://lnkd.in/dNgP7N6U #Medicine #Health #OncoDaily #Cancer #Oncology #ColorectalCancer #GlobalCancerMovement

Discussion on management of early-stage disease - International Association for the Study of Lung Cancer Narjust Florez M.D. Dana-Farber Cancer Institute Harvard Medical School ESMO - European Society for Medical Oncology #ChemoImmunotherapy #ESMO #Cancer #OncoDaily #Oncology #CancerPrevention